Figure 2From: The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age Achievement of sUA <6.0 mg/dL--All Subjects (Primary Endpoint) and by Renal Function. Data regarding the percentage of subjects with normal renal function with sUA <6.0 mg/dL is not presented due to the low number of subjects in this group (N = 6). a p = 0.029 vs allopurinol; b p ≤ 0.001 vs febuxostat 40 mg; c p < 0.001 vs allopurinol; d p = 0.004 vs allopurinol.Back to article page